Bronchiectasis phenotypes.


Journal

Current opinion in pulmonary medicine
ISSN: 1531-6971
Titre abrégé: Curr Opin Pulm Med
Pays: United States
ID NLM: 9503765

Informations de publication

Date de publication:
05 2019
Historique:
pubmed: 21 3 2019
medline: 10 4 2020
entrez: 21 3 2019
Statut: ppublish

Résumé

Bronchiectasis is a chronic respiratory disease with heterogeneous clinical manifestations and outcomes. Identifying clinical phenotypes could help in managing bronchiectasis patients and hopefully improve disease prognosis by adopting personalized treatment. We review the current literature on clinical phenotypes of bronchiectasis and try to highlight priorities for future research. Different studies have tried to stratify bronchiectasis patients according to cause, microbiology, or associated conditions. In consideration of the huge heterogeneity of bronchiectasis different cluster analyses in bronchiectasis have also been performed. Unfortunately classification by cause is clinically meaningful only in a few conditions in which specific treatment is available or a specific management is recommended. This is the case, for instance, of allergic bronchopulmonary aspergillosis, immunodeficiencies or chronic airways comorbidities of bronchiectasis, such as chronic obstructive pulmonary disease and asthma. From a clinical perspective, the microbiological cluster stratification proposed by Aliberti et al. seems the most profitable one but still so a number of host-related factors have an unpredictable effect on clinical manifestations and outcomes of bronchiectasis. Although numerous attempts to identify clinical phenotypes in bronchiectasis have been performed, currently there is need to further investigate the host-related factors (endotypes) that surely play a determinant role in disease severity.

Identifiants

pubmed: 30893106
doi: 10.1097/MCP.0000000000000569
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-288

Auteurs

Patricia Chang-Macchiu (P)

Pneumology Department, Hospital Universitari Vall d' Hebron (HUVH), Institut de Recerca Vall d'Hebron (VHIR), Barcelona, Spain.

Letizia Traversi (L)

Department of Medicine and Surgery, Respiratory Diseases, Università dell'Insubria, Varese-Como, Italy.

Eva Polverino (E)

Pneumology Department, Hospital Universitari Vall d' Hebron (HUVH), Institut de Recerca Vall d'Hebron (VHIR), Barcelona, Spain.
Pneumology Department, Hospital Universitari Vall d [Combining Acute Accent]Hebron (HUVH), Institut de Recerca Vall d'Hebron (VHIR), CIBER, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH